ArticleFrontiers in endocrinology2025
Prostogrit mitigates testosterone/estradiol induced prostatic enlargement/remodeling in rat model of benign prostatic hyperplasia and fine-tunes prostatic expression of
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Benign prostate hyperplasia (BPH), the pathological basis of benign prostatic syndrome (BPS), is an ageing-associated, androgen-driven, non-malignant growth of the prostate, with an inflammatory etiology. It is characterized by hyperproliferation of prostate cells and bothersome lower urinary tract symptoms. Current therapies for BPH provide both symptomatic relief and are disease modifying. However, they are associated with treatment limiting adverse effects. Accordingly, safer and effective alternatives to conventional treatments are required. Prostogrit is a novel, Ayurvedic medicine, indicated for the treatment of BPH. The objective of the current study was to evaluate the pharmacological effects of Prostogrit in rat model of BPH. Methods: Ultra high performance liquid chromatography was employed to detect and quantify the phytocompounds present in Prostogrit. BPH was induced in male Sprague Dawley (SD) rats by subcutaneous administration of testosterone propionate (TP) + estradiol benzoate (EB). Rats were administered Prostogrit at the doses of 10, 30, 100 and 300 mg/kg, twice daily ( Results: Phytochemical analysis of Prostogrit revealed the presence of phytometabolites, namely guggulsterone, gallic acid, 5-hydroxymethylfurfural (5-HMF), methyl gallate, cinnamic acid and piperine. In the Conclusion: The findings of the current proof of concept study suggest that Prostogrit has pharmacological effects in an animal model of BPH. Accordingly, it possesses preclinical potential for the pharmacotherapeutic management of BPH, which merits further investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.